☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Novartis
PharmaShots Weekly Snapshots (September 16 – September 20, 2024)
September 20, 2024
Novartis Reports the US FDA’s Approval of Kisqali (Ribociclib) for the Treatment of HR+/HER2- Early Breast Cancer
September 18, 2024
Novartis to Highlight Updated Data from the P-III (NATALEE) Study of Kisqali (Ribociclib) for Treating Early Breast Cancer (EBC) a...
September 16, 2024
Astellas’ Padcev Plus Keytruda Receives the EC’s Approval to Treat Advanced Urothelial Cancer
August 28, 2024
Novartis Reports Topline Data from P-III (V-MONO) Trial of Leqvio (Inclisiran) in Patients at Atherosclerotic Cardiovascular Disea...
August 28, 2024
Novartis Highlights the P-III (REMIX) Trial Data of Remibrutinib to Treat Chronic Spontaneous Urticaria at EAACI 2024
May 31, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.